Publications

• Obefazimod: a first-in-class drug for the treatment of ulcerative colitis

  Séverine Vermeire, Virginia Solitano, Laurent Peyrin-Biroulet, Herbert Tilg, Silvio Danese, Hartmut Ehrlich, Didier Scherrer, Paul Gineste, Laurence d’Agay, Bruce E Sands
  JCC, published online in May 2023

• ABX464 (obefazimod) up-regulates miR-124 to reduce pro-inflammatory markers in inflammatory bowel diseases

  Cécile Apolit, Noëlie Campos, Audrey Vautrin, Christina Begon-Pescia, Laure Lapasset, Didier Scherrer, Paul Gineste, Hartmut J. Ehrlich, Aude Garcel, Julien Santo, Jamal Tazi
  Clinical and Translational Gastroenterology, published online Jan. 2023

• ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension

  Severine Vermeire, Bruce E. Sands, Herbert Tilg, Zsolt Tulassay, Radoslaw Kempinski, Silvio Danese, Ivan Bunganič, Josianne Nitcheu, Julien Santo, Didier Scherrer, Sophie Biguenet, Hartmut J. Ehrlich, Jean-Marc Steens, Paul Gineste, William J. Sandborn
  Lancet Gastroenterol Hepatol, Volume 7, Issue 11, Sept. 2022, P. 1024-1035

• Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

  Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
  Annals of the Rheumatic Disease, 2022;81:1076–1084.

• Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial

  Severine Vermeire, Xavier Hébuterne, Herbert Tilg, Gert De Hertogh, Paul Gineste, Jean-Marc Steens
  Gastroenterology, Volume 160, Issue 7, June 2021, P. 2595-2598.E3

• Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases

  Jamal Tazi, Christina Begon-Pescia, Noëlie Campos, Cécile Apolit, AudeGarcel, DidierScherrer
  Drug Discovery Today, Volume 26, Issue 4, April 2021, P. 1030-1039

• Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

  Audrey Vautrin, Laurent Manchon, Aude Garcel, Noëlie Campos, Laure Lapasset, Abdelhamid Mahdi Laaref, Roman Bruno, Marie Gislard, Emeric Dubois, Didier Scherrer, Hartmut Ehrlich and Jamal Tazi
  Nature Scientific Reports, Volume 9, Article number: 792, January 2019

• The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

  Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos, Didier Scherrer, Hartmut J. Ehrlich, Michael Hahne & Jamal Tazi
  Nature Scientific Reports, Volume 7, Article number: 4860, July 2017

• Pharmacokinetics And Tolerability of ABX464, A Novel First-in-Class Compound To Treat HIV Infection, In Healthy HIV-uninfected Subjects.

  Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.
  Journal of Antimicrobial Chemotherapy, Volume 72, Issue 3, March 2017

• Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.

  Scherrer D, Rouzier R, Cardona M, Barrett PN, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.
  Antimicrobial Agents and Chemotherapy, Volume 61, Issue 1, January 2017

• Differential Efficacy of Abx464 and Its Primary Metabolite Abx464- Nglc on Hiv Replication In Human Pbmc’s and Macrophages: Implications for Treatment Strategies to Eliminate Virus Reservoirs

  D. Scherrer, J.-M. Steens, P. Gineste, N. Campos, A. Garcel, E. Schlaefper, R. Speck, J. Tazi, H.J. Ehrlich
  Presentation: HIV Drug Conference, October 2016

• Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment Naïve Patient

  Didier Scherrer, Jean-Marc Steens, Supparatpinyo Kuanchai, Ratanasuwan Winai, Kiat Ruxrungtham, Regine Rouzier, Jamal Tazi, Paul Gineste, Hartmut Ehrlich, Robert Murphy
  Presentation: Conference on Retroviruses and Opportunistic Infections, February 2016

• Long Lasting Control of Viral Rebound with a New Drug ABX464 Targeting Rev – Mediated Viral RNA Biogenesis

  N. Campos, R. Myburgh, A. Garcel, A. Vautrin, L. Lapasset, E. Schläpfer Nadal, F. Mahuteau-Betzer, R. Najman, P. Fornarelli, K Tantale, E. Basyuk, M. Séveno, J. Venables, B.Pau, E. Bertrand, M. Wainberg, R.Speck, D. Scherrer and J. Tazi
  Retrovirology, Volume 12, Issue 30, March 2015

• Durable Control of Viral Load Rebound In Humanized Mice By ABX464 Targeting Rev Functions

  Noelie Campos, Renier Myburgh, Aude Garcel, Audrey Vautrin, Laure Lapasset, Katjana Tantale, Mark Wainberg, Roberto Speck, Didier Scherrer, Jamal Tazi
  Presentation: Conference on Retroviruses and Opportunistic Infections, February 2015